Research Insights
Evidence-based analysis of peptide research. Research digests unpack landmark studies; trend reports surface cross-peptide patterns; evidence briefs deliver fast reads on single questions.
May 2026 in Peptides: TRIUMPH-1, the Maintenance Pivot, and the First HDV Drug
Retatrutide's 28.3% ceiling, Novo's oral GLP-1 lead, ECO's maintenance pivot, EASL MASH and HBV-cure data, and bulevirtide's first HDV approval.
Microdosing Ozempic: What the Trend Is Actually About
Sub-label GLP-1 dosing went from Reddit to a Rebel Wilson ad in eighteen months. The evidence is thin, the pharmacology unfriendly, and the real story is compounding.
GLP-1s, Pregnancy, and Birth Control: The 'Ozempic Babies' Guide
Why surprise pregnancies happen on these drugs, the tirzepatide-pill interaction that semaglutide does not share, and how long to stop before trying to conceive.
Which MASH Drug for Which Patient: A Plain-English Guide for 2026
Two years ago there were zero approved drugs for MASH, the serious form of fatty liver disease. Now there are two — Rezdiffra and semaglutide (Wegovy) — and a wave of others is close behind. EASL 2026 in Barcelona this week brought fresh data on most of them: survodutide in the NEJM, pemvidutide's 48-week results, Aligos and Akero and the rest. Here's a plain-English guide to what's available, what's coming, and how doctors are starting to match the right drug to the right patient.
Beyond GLP-1 Alone: Why Combination Therapy Is the Next Obesity Breakthrough
Single-drug GLP-1 therapy hit a ceiling at about 28-30% weight loss with retatrutide. The next jump probably won't come from another solo drug. It'll come from pairing GLP-1s with other mechanisms. EASL 2026 in Barcelona gave the strongest evidence yet: Arrowhead's experimental RNAi drug ARO-INHBE doubled weight loss and tripled fat reduction when added to a small dose of tirzepatide. Here's why combination therapy is becoming the next frontier in obesity and MASH, and what's coming.
GLP-1s and Cancer: What the Evidence Actually Shows in 2026
Roughly 30 million Americans are now on GLP-1 therapy, and the cancer angle of that drug class has shifted meaningfully over the past two years. ASCO 2026 Abstract 3143, previewed today, documented 38-50% lower metastatic progression across four obesity-related cancers in 12,112 patients. A 2025 ASCO observational study found a 7% lower incidence of fourteen obesity-related cancers in 170,000+ GLP-1 users versus DPP-4 inhibitor patients. The MTC and pancreatic cancer warnings haven't borne out in human data. Here's what the cancer evidence actually shows, where the signal is strongest, where the methodology gets soft, and how to think about the cancer angle if you're already on or considering GLP-1 therapy.
GLP-1s vs Bariatric Surgery: How to Think About the Choice in 2026
Bariatric surgery procedures dropped below 200,000 in 2024 — the first time since 2020 — as GLP-1 prescriptions grew from 4,600 in 2018 to 1.4 million in 2025. Wegovy 14.9%, Zepbound 22.5%, Wegovy HD 20.7%, and retatrutide 28.3% now overlap substantially with sleeve gastrectomy (25-30%) and Roux-en-Y gastric bypass (30-35%). Here's what the comparison actually shows, where surgery still wins, where pharmacology now wins, and how to think about your own decision.
The Dysesthesia Signal: Why Retatrutide Tingles and What It Means for Patients
20.9% of TRIUMPH-4 participants on retatrutide 12 mg and 12.5% in TRIUMPH-1 reported dysesthesia — abnormal skin sensations that didn't appear in the tirzepatide or semaglutide development programs. The signal traces to retatrutide's third receptor arm: glucagon. Here's what the trial data showed, the most-likely mechanism, why the effect is dose-dependent, and how prescribers should think about it ahead of the 2027 approval window.
Should I Wait for Retatrutide? What TRIUMPH-1's 28.3% Phase 3 Readout Just Changed About Obesity Prescribing
Eli Lilly released TRIUMPH-1 Phase 3 topline May 21: retatrutide produced 28.3% mean weight loss at 12 mg over 80 weeks, 30.3% in the 104-week BMI ≥35 extension, and 45.3% of participants reached ≥30% weight loss — bariatric-surgery territory. The NDA filing is now Q4 2026 / Q1 2027, with TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + cardiovascular disease) still pending later this year. Here's what the readout means for patients deciding between starting Wegovy or Zepbound now and waiting for retatrutide.
GPR119 Agonists: The Indirect GLP-1 Strategy Pharma Is Trying Again
Sanofi paid $375M for the lead GPR119 agonist MBX-2982 in June 2010 and walked away by May 2011. The receptor is supposed to make your gut release its own GLP-1 — and fifteen years of failed development have made that simple idea quietly contentious. MetaVia's vanoglipel posted Phase 2a MASH data at AASLD in November 2025 and lands three late-breaking posters at ADA 2026 on June 7. Here's what GPR119 actually does, why the first wave of programs failed, and what's different this time.
NK2R: The Next Obesity Receptor After GLP-1?
Novo Nordisk paid €470M for an NK2R startup in 2023. The Nature paper landed in November 2024. Tsinghua's 2026 AI peptide design competition has now picked NK2R as the benchmark target. Here's what the receptor actually does, why it could avoid the nausea problem that limits GLP-1 adherence, and the realistic timeline to clinic.
$28/Year Generic Semaglutide Is Already Possible And It Won't Reach US Patients Until 2032
A March 2026 medRxiv preprint priced generic injectable semaglutide at $28-140/person-year, and Canada, India, and Brazil are already running with that math. US patent protection on the active drug runs through December 2031. The catch isn't manufacturing — it's device patents, policy coordination, and Novo's preemptive 2027 list-price cut.
EASO First-Line: The New Obesity Treatment Algorithm by Complication, Explained
The European Association for the Study of Obesity published an updated treatment framework in Nature Medicine on May 14, 2026, formally privileging semaglutide and tirzepatide as first-line therapy across most obesity complications. The choice between them is no longer 'whichever your insurance covers' — it now depends on which complications you have.
GLP-1s After 65: What the New Data Actually Shows
Two ECO 2026 senior-population analyses — Padova's STEP pool on semaglutide 2.4 mg and Lilly's ATTAIN pool on orforglipron — finally fill a clinical gap that's existed since Wegovy launched. Here's how to read them, where the data still falls short, and what it means for prescribing in adults over 65.
How to Stay Off GLP-1s: The 2026 Maintenance Playbook
The May 12 SURMOUNT-MAINTAIN (Lancet) and ATTAIN-MAINTAIN (Nature Medicine) dual publication finally gives prescribers Phase 3 evidence for what happens when patients step down from injectable GLP-1s. Spoiler: with the right protocol, most of the weight loss stays. Without it, two-thirds comes back.
Wegovy Across Menopause: What the May 2026 Data Means for Women in Their 40s and 50s
A new STEP UP post-hoc analysis and a 34,000-woman real-world database, both presented at ECO 2026, finally answer the question many perimenopausal women have been asking: does this drug work the same way during the hormonal transition? Plus a SELECT subgroup result on cardiovascular events that's bigger than the population average.
Beyond Weight Loss: 8 Non-GLP-1 Peptides Tackling Rare Disease in 2026
While the obesity drugs eat the headlines, a second-tier pipeline of peptide therapeutics is doing real work in indications most patients have never heard of. Post-bariatric hypoglycemia, hypothalamic obesity, oral PTH for osteoporosis, oligonucleotide conjugates for DM1. Here's what's actually in the clinic and what the next 18 months look like.
AI-Designed Cyclic Peptides Are Cracking Undruggable Targets
In the last four weeks: CIP-3 hit nanomolar CD28 antagonism from an AI design pipeline, CycloSEL screened 16 million macrocycles to nail a WDR5 inhibitor, Merck published a biocatalytic synthesis that cuts oral PCSK9 step count by more than half. The cyclic-peptide drug-discovery stack just changed. Here's what's actually new.
Tired on a GLP-1? Why Retatrutide Hits Harder, and What Actually Helps
Fatigue affects 5–11% of GLP-1 users in trials — Ozempic, Wegovy, Mounjaro, Zepbound included — and retatrutide's glucagon-receptor activity gives it a different fatigue profile from the rest. Here's what's mechanism, what's calorie deficit, and what's a sourcing problem in disguise.
Tweaked Your Back? Tore Something Snowboarding? What Peptides Can and Can't Do for Injury Recovery
BPC-157, TB-500, and the Wolverine Stack get pitched as a recovery cheat code. The animal data is real, the human evidence is thinner than the marketing suggests, and the regulatory ground keeps moving.
What's Next After GLP-1: 6 Peptide-Receptor Systems Driving the Next Decade of Obesity Drugs
An April 10, 2026 Frontiers in Drug Discovery review and a companion Bloomgarden commentary in Journal of Diabetes have laid out the post-incretin research agenda. The candidates: apelin, spexin, phoenixin, relaxin-3, osteocalcin, irisin. Plus Stanford's BRP and a few others. Here's what's actually credible.
Peptide Blends vs. Separate Vials: KLOW, Glow, and Wolverine Without the Marketing
A blend is cheaper per milligram and easier to reconstitute. It also locks your ratio, hides which component caused the welt, and has zero published stability data. When the blend math works, when it doesn't, and what experienced users actually do.
April 2026 in Peptides: The Month That Reset the Industry
Foundayo's launch, the FDA Category 2 removal, Lilly's $19.8B quarter, AACR peptide oncology, and a 503B compounding proposal all in 30 days.
Peptides vs. Growth Hormone (HGH): Why the Pituitary Pathway Isn't the Same as Direct Injection
Sermorelin, CJC-1295, ipamorelin, tesamorelin, MK-677 push your pituitary to release GH. Recombinant HGH skips it entirely — that gap drives the differences.
CGRP and Migraine: The Peptide Drug Class Most Peptide-Curious People Have Never Heard Of
Eight FDA-approved drugs target the CGRP peptide. Anti-CGRP antibodies halve monthly migraine days for 30-49% of patients — peptide drug class most fans miss.
Peptides for Sleep: What the RCTs Actually Show
MK-677 boosts slow-wave sleep 50%. Three orexin antagonists are FDA-approved. DSIP — the peptide literally named for sleep — has almost no modern data.
Peptides for Gaining Weight: Lean Mass, Appetite, and the Underweight Patient
Peptides for weight gain in the underweight, post-illness, and post-GLP-1 patient: the appetite and IGF-1 effects others call side effects are the mechanism.
Blood Work Before and After Peptides: How to Actually Know If Yours Is Working
A peptide-by-peptide guide to blood work, body comp scans, and questionnaires that make a subjective protocol measurable: IGF-1, HOMA-IR, DEXA, CD4:CD8, PHQ-9.
Peptides for Anxiety, Panic, and Stress: Where the Evidence Actually Lands
Selank has RCT data vs. benzos. Oxytocin can paradoxically raise anxiety. GLP-1s show big anxiolytic signals in observational data — state of the 2026 evidence.
Peptides for Chronic Gut Issues: IBD, IBS, Leaky Gut, and the Evidence Hierarchy
Four peptides are FDA-approved for gut conditions. BPC-157 — the one everyone asks about — has a Phase 2 UC trial that was completed and never published.
Peptides for Fertility and IVF: The Clinical Evidence in 2026
Modern IVF runs on peptides. GnRH analogs power every cycle, and kisspeptin triggers may eliminate OHSS risk for high-risk patients. State of the field in 2026.
Peptides for Long COVID, ME/CFS, and Post-Viral Fatigue: What the Evidence Actually Shows
Clinics prescribe peptides for post-viral fatigue. NIH RECOVER doesn't. The gap between peptide rationale and evidence is wider than the marketing suggests.
Peptides for MCAS and POTS: The Mast Cell and Autonomic Cluster
MCAS and POTS co-occur in 66% of cases. Best peptide signal: a 47-patient GLP-1 series. Some peptides release histamine and flare what you're treating.
Peptide-Drug Conjugates: The Quiet Revolution in Targeted Cancer Therapy
Two FDA-approved drugs, 50+ in trials, and a $1.5B market by 2031 — PDCs are finally having their moment.
The Muscle-Preservation Race: Trevogrumab, Bimagrumab, Apitegromab, and the Pharmacology of Keeping Lean Mass on GLP-1s
About a third of GLP-1-induced weight loss is lean mass. Four drugs targeting the myostatin/activin pathway are now in obesity trials. COURAGE, BELIEVE, and EMBRAZE have produced the first Phase 2 readouts. What the data shows, how the mechanisms differ, and why the FDA is raising the bar.
Peptides for Acne-Prone and Post-Acne Skin: What the Evidence Actually Shows
Antimicrobial peptides kill Cutibacterium acnes in preclinical studies — but the real clinical wins for peptides in acne are on the aftermath: post-inflammatory hyperpigmentation, scar remodeling, and barrier repair. Here's the honest breakdown of mechanism vs. clinical evidence.
Peptides for Arthritis: What Actually Works, What's Still Preclinical, and What the Hype Gets Wrong
GLP-1 knee-osteoarthritis data is the strongest peptide-arthritis evidence in 2026. PEPITEM matched infliximab in mice. BPC-157 and TB-500 have one retrospective study between them. The peptide-for-arthritis story, mapped against the clinical evidence.
Eating Enough Protein — and Training Hard Enough — on GLP-1s
A San Raffaele study tracking 332 adults found that GLP-1 users consume just 0.6 g/kg/day of protein — 88% fall below even conservative guidelines. The muscle-loss data, the protein math, and why resistance training isn't optional.
The CJC-1295/Ipamorelin Flush: Why Your Face Gets Hot After the Shot
Ipamorelin was engineered specifically to eliminate the systemic flush that plagued GHRP-6. So why do users on the CJC/Ipamorelin blend still get warm-faced, tingly, and lightheaded? The answer points squarely at the DAC.
GHK-Cu Stinging and Welts: The Copper Peptide Side Effect Most Users Experience
It's not an allergy and it's not a bad batch — it's copper chemistry. Why GHK-Cu is the outlier among peptides, what's happening under your skin, and the dilution-plus-timing fix that actually works.
Why So Many People Quit GLP-1 Drugs — And How to Stay on Track
Fewer than 1 in 4 patients stay on GLP-1 medications after a year, and two-thirds of lost weight comes back after stopping. Here's what the data says about why people quit, what happens when they do, and practical strategies for sticking with it.
Tanning Peptides: Melanotan I vs Melanotan II — What the Evidence Actually Shows
One is FDA-approved with 1,000+ patients and zero melanomas. The other is an unlicensed TikTok trend linked to melanoma case reports. They share a name and a receptor — but almost nothing else.
Transitioning From Semaglutide/Tirzepatide to Retatrutide: What the Data — and Reddit — Actually Show
Retatrutide is a reset, not a continuation. Here's what the Phase 3 evidence, pharmacology, and community transition patterns say about sequencing the triple agonist after semaglutide or tirzepatide.
GLP-1 Drugs and Addiction: Can Ozempic Curb Alcohol, Opioids, and More?
A landmark study of 606,000 veterans found GLP-1 drugs reduced new substance use disorders by 14-25% and overdose deaths by 50%. From alcohol to opioids to cannabis, the reward-pathway science is catching up to what patients have been reporting for years.
When Do GLP-1 Patents Expire? The Complete Generic Timeline
Semaglutide patents are already expiring outside the US, generic liraglutide launched in 2025, and tirzepatide is locked up until 2036. Here's when each GLP-1 drug becomes available as a generic — and what that means for cost.
Peptides and Sports: Which Ones Will Get You Banned
From CrossFit to UFC, athletes are catching multi-year bans for peptides like BPC-157, CJC-1295, and TB-500. Here's exactly what WADA prohibits, who's been caught, and what competitive athletes need to know.
The Peptide Quality Crisis: What Investigations Found and How to Protect Yourself
Within two weeks in April 2026, ProPublica, The New Yorker, The Guardian, NBC News, and regulators in three countries reached the same conclusion: a lot of what people are injecting isn't what's on the label.
Peptides and the Menstrual Cycle: What Research Shows About Timing, Side Effects, and Hormonal Interactions
GLP-1 nausea is worse when estrogen peaks. GH secretagogue response varies by cycle phase. Kisspeptin sensitivity shifts across the month. Here's what the science says about how peptides interact with the menstrual cycle.
The Peptide Skin-Brightening Lineup: Glutathione, Nonapeptide-1, Oligopeptide-68, and Decapeptide-12
Hydroquinone, kojic acid, and arbutin dominate the hyperpigmentation market — but a new generation of peptides targets melanin synthesis at four different points in the pathway, often with far better safety profiles. Here's what the clinical evidence actually shows for each.
Looksmaxxing Peptides: The Evidence Behind the Aesthetic Optimization Trend
From Retatrutide body recomposition to GHK-Cu skin protocols, peptide stacks have become the backbone of the looksmaxxing movement. We break down what the science actually supports — and where the hype runs ahead of the data.
Peptide Stacking with GLP-1s: What People Are Combining with Ozempic and Mounjaro
GLP-1 drugs work — but muscle loss, GI distress, and skin laxity have people adding BPC-157, GH secretagogues, and more. Here's what the stacking rationale looks like, and where the evidence actually is.
Peptides for Running, Cardio, and Endurance: Recovery, Performance, and What the Evidence Shows
From BPC-157 for tendon injuries to MOTS-c for mitochondrial performance, runners are turning to peptides for an edge. Here's what actually has data behind it — and what's still a bet on animal studies.
Foundayo vs Oral Wegovy: The Battle of the GLP-1 Pills
Eli Lilly's small-molecule pill vs Novo Nordisk's peptide tablet. One is more convenient, the other more effective. Here's what the data shows — and why no head-to-head trial exists yet.
Peptide Injection Site Reactions: Histamine, Mast Cells, and What's Normal
That red, itchy welt after your CJC-1295/Ipamorelin shot isn't an allergy — it's mast cell degranulation, and some peptides trigger it far more than others. Here's the science, the spectrum, and when to actually worry.
Oral vs Injectable Peptides: What Foundayo's Approval Means for the Future
Eli Lilly's oral GLP-1 pill eliminates injections entirely. Here's how oral and injectable peptide delivery compare — and why the future of peptide therapy may be swallowed, not injected.
The Most Popular Peptides of 2026
From oral GLP-1 pills and triple agonists to the FDA reclassification saga and a copper peptide going viral — what's driving 10 million monthly peptide searches.
Will Peptides Work for Me? What Genetics, Sex, and Phenotype Tell Us
A landmark 2026 Nature study of 27,885 people found genetic variants that predict GLP-1 drug response. But genetics is just one piece — here's the full picture of why peptides work differently for different people.
Weight Loss Peptides and Muscle Loss: The Problem, the Science, and How to Protect Lean Mass
GLP-1 drugs produce dramatic fat loss — but 25-40% of weight lost is muscle. New combinations like bimagrumab + semaglutide and next-gen drugs like retatrutide may change that equation.
GLP-1 Drugs and Emotional Flattening: What We Know and Don't Know
Reports of reduced libido, emotional blunting, and 'falling out of love' on semaglutide and retatrutide are growing. The neuroscience is plausible — but the clinical evidence is still early.
Supplements That Stack Well with Peptides: An Evidence-Based Guide
From creatine for GLP-1 muscle preservation to zinc for thymic peptides and magnesium for sleep-stack GH protocols — what the research supports.
Peptide Legality in 2026: FDA Status, Compounding, and the RFK Reclassification
The regulatory landscape for peptides is shifting fast. Here's what's actually changed, what's still pending, and how to legally access peptide therapy in 2026.
Ozempic Alternatives in 2026: Compounded Semaglutide, New Drugs, and What to Know
Brand-name GLP-1 drugs cost $1,000+/month. Here's a research-backed look at compounded semaglutide, tirzepatide, oral options, and what's coming next.
Peptides for Women: What the Research Shows
From FDA-approved sexual health treatments to weight loss, skincare, and fertility — a research-backed look at which peptides have been studied in women and what the evidence says.
Best Peptides for Muscle Growth: What the Evidence Actually Shows
GH secretagogues, IGF-1 variants, and recovery peptides can support lean mass — but the effects are modest compared to steroids. Here's the honest breakdown.
Peptides vs Steroids: A Complete Comparison
Peptides and anabolic steroids are fundamentally different — in mechanism, safety, legality, and what they can realistically achieve. Here's what the evidence shows.
Peptides for Hair Growth: GHK-Cu, TB-500, and What the Research Shows
Copper peptides lead the evidence for peptide-based hair regrowth. Here's what's proven, what's promising, and what's hype.
LL-37 and the Antimicrobial Peptide Frontier
As antibiotic resistance grows, host defense peptides like LL-37 are being studied as a fundamentally different approach to fighting infection.
The Evidence Gap: Which Popular Peptides Have Almost No Human Data?
A frank look at the disconnect between online popularity and clinical evidence for some of the most popular peptides.
BPC-157 and Gut Healing: What 30+ Studies Actually Show
The most-cited peptide in the Atlas has a mountain of preclinical data. We break down what's proven, what's promising, and what's still missing.
GLP-1 Agonists Beyond Weight Loss
What 100+ clinical trials reveal about semaglutide, tirzepatide, and the next generation of incretin therapies — from cardiovascular protection to neurodegeneration.
The Mitochondrial Peptide Revolution
MOTS-c, SS-31, and Humanin are rewriting our understanding of aging at the cellular level. Here's what the research actually shows.
MK-677: The Oral Growth Hormone Secretagogue With 15 RCTs
One of the most studied non-injectable peptide mimetics — what the clinical trial evidence shows about sleep, muscle, bone, and the IGF-1 axis.
Neuropeptides in 2026: Where the Research Actually Stands
Semax, Selank, Cerebrolysin, and Dihexa — separating clinical evidence from online hype in the cognitive enhancement space.
Tesamorelin: From HIV Lipodystrophy to Liver Health and Cognitive Enhancement
How a growth hormone-releasing peptide with 20+ RCTs became one of the most evidence-backed peptides in clinical medicine.
Thymic Peptides and Immune Restoration
Thymosin Alpha-1, Thymalin, and Thymulin — how thymus-derived peptides are being studied to combat immunosenescence and age-related immune decline.